Pzena Investment Management LLC Purchases 91,305 Shares of Pfizer Inc. $PFE

Pzena Investment Management LLC raised its position in Pfizer Inc. (NYSE:PFE) by 1.5% in the 3rd quarter, Holdings Channel.com reports. The fund owned 6,050,227 shares of the biopharmaceutical company’s stock after acquiring an additional 91,305 shares during the quarter. Pzena Investment Management LLC’s holdings in Pfizer were worth $172,552,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Retirement Wealth Solutions LLC increased its position in shares of Pfizer by 144.6% during the third quarter. Retirement Wealth Solutions LLC now owns 861 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 509 shares in the last quarter. Keb Asset Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter worth $26,000. Field & Main Bank acquired a new stake in shares of Pfizer in the 2nd quarter worth $27,000. Bullseye Investment Management LLC purchased a new position in Pfizer during the 2nd quarter worth $28,000. Finally, Timbuktu Capital Management LLC purchased a new position in Pfizer during the 2nd quarter worth $29,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, August 31st. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. UBS Group lifted their price objective on shares of Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Wednesday. BMO Capital Markets dropped their price objective on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating on the stock in a report on Monday, July 13th. Finally, Bank of America reduced their target price on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, July 10th. Five research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $29.81.

Pfizer Stock Performance

NYSE PFE opened at $30.79 on Thursday. The firm has a market capitalization of $175.52 billion, a P/E ratio of 43.99, a PEG ratio of 2.04 and a beta of 0.31. The stock has a 50-day simple moving average of $28.69 and a two-hundred day simple moving average of $26.86. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27. Pfizer Inc. has a fifty-two week low of $23.62 and a fifty-two week high of $31.06.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 EPS for the quarter, topping analysts’ consensus estimates of $0.74 by $0.13. The firm had revenue of $16.58 billion for the quarter, compared to the consensus estimate of $15.85 billion. Pfizer had a return on equity of 19.98% and a net margin of 6.34%. The company’s revenue was down .4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.87 earnings per share. On average, equities analysts forecast that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 7th. Stockholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is 226.32%.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised its 2026 revenue outlook to $62–$64 billion and adjusted EPS forecast to $2.95–$3.05, citing execution and cost savings. Reuters article
• Positive Sentiment: Growth in newer and acquired medicines is helping offset pandemic-product declines: these products grew 32% operationally in Q3, while non-COVID products overall grew 7%. This supports Pfizer’s effort to build growth beyond COVID sales. The Motley Fool article
• Positive Sentiment: Scotiabank raised its price target to $35 and maintained a “sector outperform” rating, signaling further potential upside. Ticker Report article
• Neutral Sentiment: Pfizer named Cecile Guegan permanent CFO after she served in the interim role. The appointment provides leadership continuity, though its near-term financial impact is unclear. Business Wire announcement
• Negative Sentiment: COVID-related product sales continued to decline, and revenue was slightly lower year over year. UBS and Citi raised their targets to $30 and RBC to $28, but each retained a neutral or sector-perform rating—targets below the recent share price that may temper expectations. UBS rating

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.